From the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Cancer J. 2022;28(2):118-120. doi: 10.1097/PPO.0000000000000584.
The COVID-19 (coronavirus disease 2019) pandemic has worldwide implications on health care, especially in our most vulnerable population: cancer patients. Flexibility and adaptation are needed to continue clinical research and for clinical trial development. At the Intramural Research Program, National Cancer Institute, swift changes have been implemented to protect our patients while maintaining the scientific integrity of our cancer clinical trials. Many lessons have been learned including incorporation of telehealth into clinical trials, partnerships with the oncology community at both academic institutions and community practices, focusing on diversity and inclusion to improve scientific innovation, and strengthened relationships with regulatory agencies and institutional review boards. These changes will enhance the clinical trials we conduct well beyond the pandemic.
COVID-19（冠状病毒病 2019）大流行对全球的医疗保健产生了影响，尤其是对我们最脆弱的人群：癌症患者。需要灵活性和适应性来继续临床研究和临床试验的开发。在国家癌症研究所的院内研究计划中，我们已经迅速采取措施来保护我们的患者，同时保持癌症临床试验的科学完整性。我们吸取了许多经验教训，包括将远程医疗纳入临床试验，与学术机构和社区实践中的肿瘤学社区建立合作伙伴关系，注重多样性和包容性以提高科学创新能力，以及加强与监管机构和机构审查委员会的关系。这些变化将增强我们在大流行之外进行的临床试验。
